Biodesix, Inc.
NASDAQ · us_market
No AI summary generated yet for this ticker.
Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to guide treatment decisions. In addition, the company provides diagnostic solutions, including translational research, initial biomarker discovery, assay design, development and validation, testing of clinical trial samples, regulatory, reimbursement, commercialization, and logistical support services for biopharmaceutical, life sciences, and diagnostic companies. Further, it operates laboratories. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Louisville, Colorado.
Here is how Adicet Bio, Inc. (ACET) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
The mean of analysts' price targets for Biodesix (BDSX) points to a 104.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The mean of analysts' price targets for Biodesix (BDSX) points to a 104.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Biodesix, Inc. (NASDAQ:BDSX) is one of the best oversold growth stocks to invest in now. Canaccord lifted the price target on Biodesix, Inc. (NASDAQ:BDSX) to $22 from $20 on May 5, reiterating a Buy rating on the shares. The firm stated that the price target increase is driven primarily by raised revenue assumptions and operating margin […]
Biodesix, Inc. (NASDAQ:BDSX) is one of the best oversold growth stocks to invest in now. Canaccord lifted the price target on Biodesix, Inc. (NASDAQ:BDSX) to $22 from $20 on May 5, reiterating a Buy rating on the shares. The firm stated that the price target increase is driven primarily by raised revenue assumptions and operating margin […]
LOUISVILLE, Colo., May 21, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that members of the Biodesix leadership team will participate in three upcoming investor conferences: Craig-Hallum 23rd Annual Institutional Investor Conference1x1 meetings only Date: Thursday, May 28, 2026Location: Minneapolis, MN William Blair 46th Annual Growth Stock ConferencePresentation and 1x1 meetings Presentation Date and Time: Wednesday, June 3, 20
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Here is how ALX Oncology Holdings Inc. (ALXO) and Biodesix, Inc. (BDSX) have performed compared to their sector so far this year.
Includes real-world clinical data from Biodesix researchers and independent Healthcare ProfessionalsLOUISVILLE, Colo., May 11, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced that additional real-world clinical and economic data related to Nodify Lung® testing will be shared at the American Thoracic Society (ATS) Annual Meeting, May 15 – 20, 2026 | Orlando, FL. The presentations further reinforce the accelerating adoption of Biodes
The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
The mean of analysts' price targets for Biodesix (BDSX) points to a 103.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Canaccord Genuity analyst Kyle Mikson maintains Biodesix (NASDAQ:BDSX) with a Buy and raises the price target from $20 to $22.
Moby summary of Biodesix, Inc.'s Q1 2026 earnings call
Moby summary of Biodesix, Inc.'s Q1 2026 earnings call
Scott Hutton: Thank you, Christopher F. Brinzey, and thank you all for joining today. Biodesix, Inc. delivered an exceptional start to 2026 with first quarter results that demonstrate continued momentum across our commercial, operational, and strategic priorities. Revenue growth accelerated, margins expanded, and we continued to demonstrate operating leverage as we progress towards profitability.
Scott Hutton: Thank you, Christopher F. Brinzey, and thank you all for joining today. Biodesix, Inc. delivered an exceptional start to 2026 with first quarter results that demonstrate continued momentum across our commercial, operational, and strategic priorities. Revenue growth accelerated, margins expanded, and we continued to demonstrate operating leverage as we progress towards profitability.
Biodesix (NASDAQ:BDSX) reported first-quarter 2026 results that company leadership said reflected accelerating revenue growth, expanding margins, and continued operating leverage as it works toward profitability. First-quarter results and updated outlook Chief Executive Officer Scott Hutton said Bi
Biodesix (NASDAQ:BDSX) reported first-quarter 2026 results that company leadership said reflected accelerating revenue growth, expanding margins, and continued operating leverage as it works toward profitability. First-quarter results and updated outlook Chief Executive Officer Scott Hutton said Bi
Scott Hutton: Thank you, Chris, and thank you all for joining us today. At Biodesix, our mission is to transform patient care and improve outcomes through personalized diagnostics that are timely, accessible and address immediate clinical needs.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| TwoSigma | quant | 45.2K | $655.85K | 0.00% | New | 2026-03-31 |
| StateStreet | passive | 17.8K | $258.13K | 0.00% | Unchanged | 2026-03-31 |
| RenTech | quant | 11.9K | $173.25K | 0.00% | New | 2026-03-31 |
| FidelityFMR | fundamental | 1 | $15 | 0.00% | Unchanged | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | -0.92 | — | — |
| 2026-05-04 | -1.10 | -0.81 | +26.09% |
| 2026-02-26 | -0.87 | -0.49 | +43.42% |
| 2025-11-03 | -1.51 | -1.16 | +22.97% |
| 2025-08-07 | -1.37 | -1.60 | -17.07% |
| 2025-05-13 | -1.40 | -1.60 | -14.29% |
| 2025-03-03 | -1.33 | -1.20 | +10.00% |
| 2024-11-01 | -1.52 | -1.40 | +7.89% |
| 2024-08-07 | -1.84 | -1.60 | +13.04% |
| 2024-05-08 | -2.87 | -2.80 | +2.33% |
| 2024-03-01 | -2.20 | -2.00 | +9.09% |
| 2023-11-07 | -3.00 | -2.80 | +6.67% |
| 2023-08-07 | -4.13 | -3.40 | +17.74% |
| 2023-05-11 | -4.73 | -4.80 | -1.41% |
| 2023-03-06 | -5.55 | -7.00 | -26.13% |
| 2022-11-03 | -6.55 | -6.80 | -3.82% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BDSX | +47.29% | +5.29% | +140.00% | +170.20% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +44.32% | +9.93% | +143.44% | +157.51% |